BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 21362317)

  • 1. Design of functional small interfering RNAs targeting amyotrophic lateral sclerosis-associated mutant alleles.
    Geng CM; Ding HL
    Chin Med J (Engl); 2011 Jan; 124(1):106-10. PubMed ID: 21362317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-mismatched siRNAs enhance selective gene silencing of a mutant ALS-causing allele.
    Geng CM; Ding HL
    Acta Pharmacol Sin; 2008 Feb; 29(2):211-6. PubMed ID: 18215350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis.
    Ding H; Schwarz DS; Keene A; Affar el B; Fenton L; Xia X; Shi Y; Zamore PD; Xu Z
    Aging Cell; 2003 Aug; 2(4):209-17. PubMed ID: 12934714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Designing siRNA that distinguish between genes that differ by a single nucleotide.
    Schwarz DS; Ding H; Kennington L; Moore JT; Schelter J; Burchard J; Linsley PS; Aronin N; Xu Z; Zamore PD
    PLoS Genet; 2006 Sep; 2(9):e140. PubMed ID: 16965178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An RNAi strategy for treatment of amyotrophic lateral sclerosis caused by mutant Cu,Zn superoxide dismutase.
    Xia XG; Zhou H; Zhou S; Yu Y; Wu R; Xu Z
    J Neurochem; 2005 Jan; 92(2):362-7. PubMed ID: 15663483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allele-specific RNAi selectively silences mutant SOD1 and achieves significant therapeutic benefit in vivo.
    Xia X; Zhou H; Huang Y; Xu Z
    Neurobiol Dis; 2006 Sep; 23(3):578-86. PubMed ID: 16857362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. siRNA-based inhibition specific for mutant SOD1 with single nucleotide alternation in familial ALS, compared with ribozyme and DNA enzyme.
    Yokota T; Miyagishi M; Hino T; Matsumura R; Tasinato A; Urushitani M; Rao RV; Takahashi R; Bredesen DE; Taira K; Mizusawa H
    Biochem Biophys Res Commun; 2004 Jan; 314(1):283-91. PubMed ID: 14715277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo application of an RNAi strategy for the selective suppression of a mutant allele.
    Kubodera T; Yamada H; Anzai M; Ohira S; Yokota S; Hirai Y; Mochizuki H; Shimada T; Mitani T; Mizusawa H; Yokota T
    Hum Gene Ther; 2011 Jan; 22(1):27-34. PubMed ID: 20649474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [RNAi and neurological disease].
    Yokota T
    Rinsho Shinkeigaku; 2005 Nov; 45(11):973-5. PubMed ID: 16447777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNA interference-mediated silencing of mutant superoxide dismutase rescues cyclosporin A-induced death in cultured neuroblastoma cells.
    Maxwell MM; Pasinelli P; Kazantsev AG; Brown RH
    Proc Natl Acad Sci U S A; 2004 Mar; 101(9):3178-83. PubMed ID: 14981234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silencing strategies for therapy of SOD1-mediated ALS.
    van Zundert B; Brown RH
    Neurosci Lett; 2017 Jan; 636():32-39. PubMed ID: 27507699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic gene silencing delivered by a chemically modified small interfering RNA against mutant SOD1 slows amyotrophic lateral sclerosis progression.
    Wang H; Ghosh A; Baigude H; Yang CS; Qiu L; Xia X; Zhou H; Rana TM; Xu Z
    J Biol Chem; 2008 Jun; 283(23):15845-52. PubMed ID: 18367449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of allele discrimination by introduction of nucleotide mismatches into siRNA in allele-specific gene silencing by RNAi.
    Ohnishi Y; Tamura Y; Yoshida M; Tokunaga K; Hohjoh H
    PLoS One; 2008 May; 3(5):e2248. PubMed ID: 18493311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model.
    Ralph GS; Radcliffe PA; Day DM; Carthy JM; Leroux MA; Lee DC; Wong LF; Bilsland LG; Greensmith L; Kingsman SM; Mitrophanous KA; Mazarakis ND; Azzouz M
    Nat Med; 2005 Apr; 11(4):429-33. PubMed ID: 15768029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS.
    Raoul C; Abbas-Terki T; Bensadoun JC; Guillot S; Haase G; Szulc J; Henderson CE; Aebischer P
    Nat Med; 2005 Apr; 11(4):423-8. PubMed ID: 15768028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Gene therapy of ALS with short interfering RNA].
    Yokota T
    Brain Nerve; 2007 Oct; 59(10):1187-94. PubMed ID: 17969360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metal-deficient SOD1 in amyotrophic lateral sclerosis.
    Hilton JB; White AR; Crouch PJ
    J Mol Med (Berl); 2015 May; 93(5):481-7. PubMed ID: 25754173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cu/Zn superoxide dismutase (SOD1) mutations associated with familial amyotrophic lateral sclerosis (ALS) affect cellular free radical release in the presence of oxidative stress.
    Cookson MR; Menzies FM; Manning P; Eggett CJ; Figlewicz DA; McNeil CJ; Shaw PJ
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2002 Jun; 3(2):75-85. PubMed ID: 12215229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short interfering RNA (siRNA) as a novel therapeutic.
    Pushparaj PN; Melendez AJ
    Clin Exp Pharmacol Physiol; 2006; 33(5-6):504-10. PubMed ID: 16700886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superoxide dismutase 1 mutants related to amyotrophic lateral sclerosis induce endoplasmic stress in neuro2a cells.
    Oh YK; Shin KS; Yuan J; Kang SJ
    J Neurochem; 2008 Feb; 104(4):993-1005. PubMed ID: 18233996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.